Journal of ISSN: 2473-0831 JAPLR

Analytical & Pharmaceutical Research
Research Article
Volume 2 Issue 1 - 2016
Method Development and Validation for Fingolimod by HPLC/UV in Immediate-Release Oral Capsule and Study the Effect of Excipients on Solubility and Dissolution Behavior
Islam A Osman1* and Emad B Basalious2
1Pharmaceutical chemistry Department, Dublin City University, Ireland
2Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, 11562, Cairo, Egypt
Received: August 17, 2015| Published: January 28, 2016
*Corresponding author: Islam A Osman, Pharmaceutical chemistry Department, Dublin City University, Al-Obour, Cairo, Egypt, Tel: +201003420050; Email:
Citation: Osman IA, Basalious EB (2016) Method Development and Validation for Fingolimod by HPLC/UV in Immediate-Release Oral Capsule and Study the Effect of Excipients on Solubility and Dissolution Behavior. J Anal Pharm Res 2(1): 00008.DOI: 10.15406/japlr.2015.02.00008

Abstract

A simple, selective, linear, precise, and accurate RP-HPLC method was developed and validated for the Quantitation of Fingolimod Hydrochloride from bulk and formulations. Chromatographic separation was achieved isocratically on Zorbax Plus C 8 column (250×4.6 mm, 5μ particle size) using a mobile phase, Acetonitrile and Di-butyl ammonium phosphate buffer in the ratio of 45:55 v/v. The flow rate was 2.0 ml/min and effluent was detected at 198 and 100μl of sample was injected. Linearity was observed in the concentration range of 0.224 - 1.68 μg/ml. The percentage RSD for precision and accuracy of the method was found to be less than 2%. The method was validated according to the ICH guidelines with respect to specificity, linearity, accuracy, precision and robustness. The method developed can be used for the routine analysis of Fingolimod hydrochloride. BCS class of Fingolimod was determined by testing solubility, dissolution profile and lipophilicity by partition coefficient.

Keywords: Fingolimod; Sclerosis; Hydrochloride; Modulating; Analysis

Abbreviations

RP: Reverse Phase; HPLC: High-Performance Liquid Chromatography; UV: Ultra Violet; LC: Liquid Chromatography; MS: Mass Spectrometry; DAD: Diode Array Detectors; LOD: Limit of Detection; LOQ: Limit of Quantification; RSD: Reflex Sympathetic Dystrophy; DSC: Differential scanning Calorimetry

Introduction

Fingolimod (2-amino-2-[2-(4-octylphenyl) ethyl] propane-1, 3-diol hydrochloride) is an immune modulating drug, it is used mainly for multiple sclerosis. It reduces the rate of relapses in relapsing-remitting multiple sclerosis by over half, but has serious adverse effects (Figure 1) [1-3].

Figure 1: N=57; Epidemiological distribution of the pathological fractures, traumatic fractures, and nonunion.

This paper is composed of two parts. The first part focuses on Quantitative determination of Fingolimod hydrochloride using RP-HPLC-UV in the concentration of dissolution instead of LC/MS in Fingolimod HGC.

 The second part is a study of Fingolimod hydrochloride dissolution profile in different media compared with reference drug and the effect of excipients on dissolution

Instrumentation, Reagents and Chemicals

Agilent 1260 HPLC system equipped with Zorbax Plus C8, 250x4.6mm, 5μm column, DAD detector N-dibutyl amine, orthophosphoric acid of analytical Grade, water and acetonitrile (HPLC grade) Fingolimod hydrochloride Working standard.

Procedure

Preparation of buffer solution (Dibutyl ammonium phosphate)

Add 8.3 ml Orthophosphoric acid to 20 ml N-dibutyl amine while stirring and addition of water to 100 ml then adjust to pH 2.5 then complete the volume to exactly 1000 ml purified water.

Mechanism of detection

Dibutyl ammonium phosphate is ion-pair reagent which used as mobile phase to attract to Fingolimod hydrochloride molecules that result in demolishing tailing in Fingolimod peak and increase UV absorbance of whole molecule hence it increase method sensitivity up to 200 mg/ml (Figure 2).

Figure 2: Structure of Dibutylammonium phosphate.

Chromatographic condition

Fingolimod was eluted in Zorbax Plus C8, 250x4.6mm, 5μm column using a mobile phase mixture of buffer and acetonitrile in the ratio of 55:45 % v/v at temperature 30°C. The lambda max of the drug in mobile phase was 198 nm, so column outlet was monitored at 198 nm. The injection volume was 100μL, flow rate 2.0 ml/min and the total runtime was 5 min.

Standard solution preparation

Dissolve accurately weighed 28mg Fingolimod Hydrochloride in to a 250 ml volumetric flask, add about 150 ml of solvent (Acetonitrile: water 1:1) then sonicate for about 10 min then complete to volume with the same solvent , then dilute 1.0 ml of Solution to 100 ml with the mobile phase (Figure 3).

Construction of Calibration Curve

The standard Fingolimod Hydrochloride solution was further diluted in 100 ml volumetric flask to obtain various concentrations ranging from 0.224 to 1.68μg/ml. From this each standard solutions 100μL was injected in to the HPLC system. The chromatograms were recorded. The concentrations of the Fingolimod Hydrochloride in μg/ml is taken in X axis and peak area of the individual concentrations of standard solution were taken in Y axis. The calibration graph was plotted (Figure 4) (Table 1) [4,5].

Limit of Quantitation and Limit of Detection

LOQ and LOD were calculated using HPLC Agilent Chemstation to find the ratio of signal to noise 10:1 and 3.3:1for LOQ and LOD respectively. The limit of Quantitation is found to be 112 mg/ml while the limit of detection is 56 mg/ml

Precision

To demonstrate agreement among results, a series of measurements are done with Fingolimod hydrochloride ten replicate injections of the specific standard at various time intervals on the same day were injected into the chromatograph and the value of %RSD was found to 1.26%. In inter-day precision same standard was injected on different days and the found %RSD was 1.68% [4,5].

Accuracy

Accuracy was done by recovery study using standard addition method, known amount of standard Fingolimod into pre-analyzed samples and subjected to proposed HPLC method. The results of recovery studies are shown in (Table 2) [4,5].

Dissolution Profile

The formula of Fingolimod capsule contains only mannitol and magnesium stearate [6]. Dissolution is performed through three standard media using apparatus 1 (Basket) and 100. RPM at 37.5 ºC and the volume of media is 500 ml the sample directly injected to HPLC (Figure 5) (Table 3) [7].        

Dissolution in pH 2.0 media the samples gives more than 85% in the first 5 min. While in acetate media pH 4.5 the dissolution rate decreased but still more than 85% in 30 min but it is less than 80% after 15 min. the dissolution in acetate media was repeated after removal of magnesium stearate from the capsule to find out that dissolution rate exceed 85% in the first 15 min (Table 4) (Figure 6).

On the other hand in phosphate media pH 6.8 the dissolution does not exceed 25% after 30 min and these results are very similar to reference drug of Novartis.

However it was observed that the dissolution of Fingolimod Hydrochloride doubled to reach 50% after 30 min in Phosphate media pH 6.8 unless magnesium stearate is added in the formula (Table 5) (Figure 7).

Magnesium stearate in acidic media has no effect due to high solubility of Fingolimod hydrochloride in acidic media.

Influence of Magnesium Stearate on Fingolimod Hydrochloride

During dissolution it was observed that absence of magnesium stearate from the formula rises the rate of dissolution especially in acetate and phosphate media therefore IR test and Differential scanning Calorimetry (DSC) to assure the relation either hydrophobic effect or hydrogen bonding [8].

IR scanning of Fingolimod and Magnesium stearate mixture show that the peak of O-H at 3400 cm-1 in Fingolimod IR Spectrum has been diminished and the strength of C=O peak in magnesium stearate IR spectrum at 1650 cm-1 has decreased in mixture sample spectrum [9] (Figure 8-11).

This interaction has been confirmed by performing DSC for Fingolimod hydrochloride and magnesium stearate mixture which show increase in heat absorbance for both magnesium stearate and Fingolimod hydrochloride compared with each standard separately which indicates presence of hydrogen bonding. On the other hand, hydrophobic effect is always accompanied with decrease in heat absorbance (Figure 12) [10,11].

Conclusion

The developed RP-HPLC method was validated and the system suitability studies were performed and all parameters combined with the simplicity and ease of operation ensures that the validated method can successfully be used for routine analysis of Fingolimod hydrochloride in bulk and capsule dosage formulation. Although magnesium stearate has influence on Fingolimod hydrochloride solubility, it has no effect on its bioavailability.          

References

  1. http://en.wikipedia.org/wiki/Fingolimod
  2. http://www.rxlist.com/gilenya-drug.htm
  3. http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf
  4. ICH (1994) Q2 (R1) Validation of Analytical Procedures: Text and Methodology. European Medicines Agency, london, UK, p. 1-15.
  5. ICH (1996) Q2B Guideline Validation of Analytical Procedures Methodology: Comments for its application. p: 71-76.
  6. Kathiresan K, Bhagath Kumar M, Moorthin C, Ahamed Ds, Kiran K (2012) Formulation and Evaluation of Fingolimod Capsules. Int J Pharm Pharm Sci 4(1): 289-292.
  7. Shayne Cox Gad (2008) Pharmaceutical Manufacturing Handbook. Regulations and Quality, John Wiley & Sons, USA, pp. 1-857.
  8. Is magnesium stearate safe to use as a supplement excipient?
  9. Iþýldak O, Sari A (2006) Adsorption properties of stearic acid onto untreated kaolinite. Chemical Society of Ethiopia Bulletin of the Chemical Society of Ethiopia 20(2): 259-267.
  10. Bruylants G, Wouters J, Michaux C (2005) Differential scanning calorimetry in life science: thermodynamics, stability, molecular recognition and application in drug design. Curr Med Chem 12(17): 2011-2020.
  11. Loladze VV, Ermolenko DN, Makhatadze GI (2001) Heat capacity changes upon burial of polar and nonpolar groups in proteins. Protein Sci 10(7): 1343-1352.
© 2014-2016 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://medcraveonline.com
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy